Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Other

Revive Therapeutics primes the pump on Bucillamine

By The Northwire Desk — AI Analysis Dec 15, 2025 · 17:09 RVV · 0.015 Revive Therapeutics Ltd
RVV · Price

Executive Summary

  • Revive Therapeutics Ltd. provided an update on its collaborative research study with Defence R&D Canada (DRDC) evaluating Bucillamine as a potential treatment for nerve agent-induced brain injury.
  • The study is expected to conclude with results in January 2026.
  • Any findings from the study will be released only with the express authorization of DRDC.

Key Details

  • Study Subject: Evaluation of Bucillamine as a potential treatment for nerve agent exposure.
  • Collaborator: Defence R&D Canada -- Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence.
  • Study Status: The research is ongoing and expected to conclude in January 2026.
  • Data Release Protocol: Findings will be released only with the express authorization of DRDC.
  • Company Focus: Revive Therapeutics is a life sciences company focused on R&D for infectious diseases and medical countermeasures, leveraging U.S. government regulatory incentives.

Notable Quotes

  • "After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January, 2026."
  • "Any findings from the study will be released only with the express authorization of DRDC."
Read the original news release →

More from Revive Therapeutics Ltd

Jun 26, 2026 · 16:15

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

Financings Jun 08, 2026 · 08:04

Canadian Investment Regulatory Organization Trading Halt - RVV

Regulatory May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Feb 27, 2026 · 18:58

SEDAR Interim Financial Statements

None